K-PAX Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://kpaxhealth.com
Methylphenidate Plus GWI-Nutrient Formula as a Treatment for Patients With Gulf War Illness
Phase 2
- Conditions
- Gulf War Illness
- Interventions
- Drug: Methyl-P plus GWI Nutrient Formula
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- K-PAX Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT02357030
- Locations
- 🇺🇸
Veterans Administration Palo Alto Health Care System (VAPAHCS), Palo Alto, California, United States
The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome
Phase 2
- Conditions
- Chronic Fatigue Syndrome (CFS)Myalgic Encephalomyelitis (ME)
- Interventions
- Drug: Methyl-P plus Nutrient FormulaDrug: Methyl-P plus Nutrient matched placebos
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- K-PAX Pharmaceuticals, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT01966276
- Locations
- 🇺🇸
Nova Southeastern University, Fort Lauderdale, Florida, United States
🇺🇸Stanford Chronic Fatigue Syndrome/ME Initiative, Stanford, California, United States
🇺🇸Fatigue Consultation Clinic, Salt Lake City, Utah, United States
© Copyright 2025. All Rights Reserved by MedPath